Faeth Therapeutics, Inc. FTH
12.92 USD +0.24 (+1.89%)
At closeNov 10, 2026, 4:00 PM EST
12.78 -0.14 -1.07%
After hours · Nov 10, 4:00 PM ET
11.83 Day range 13.93
7.45 52-week range 42.14
- YTD
- +21.09%
- 1 year
- +34.44%
News
benzinga.com Citigroup Maintains Buy on Faeth Therapeutics, Raises Price Target to $60 Citigroup analyst Geoff Meacham maintains Faeth Therapeutics (NASDAQ:FTH) with a Buy and raises the price target from $55 to $60.
benzinga.com Crude Oil Falls Over 3%; NRG Energy Shares Jump After Strong Q3 Results U.S. stocks surged Monday, led by a 2.1% S&P 500 gain; NRG jumped on strong results, while Zura Bio plunged 75% after trial failures.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
benzinga.com Dow Jumps Over 600 Points; Constellation Energy Posts Upbeat Earnings U.S. stocks rallied Monday, led by tech and consumer discretionary shares. Constellation Energy beat Q3 estimates; oil fell while gold rose.
benzinga.com Faeth Therapeutics Announces Data From Its Phase 2 Study Of PIKTOR Shows Confirmed Objective Response Rate OF 33%, Disease Control Rate Of 83% Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced topline clinical data from…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers MaxCyte (NASDAQ:MXCT) stock increased by 21.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $130.0 million. Vir Biotechnology (NASDAQ:VIR)…
benzinga.com Why Greenfire Resources Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket Greenfire shares surged 25% after Strathcona announced a C$2.7B-C$2.9B acquisition; several small-cap stocks posted sharp premarket gains and losses.- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock increased by 17.5% to $0.06 during Friday's after-market session. The company's market cap stands at $1.3 million. Nkarta (NASDAQ:NKTX) stock…
benzinga.com Faeth Therapeutics To Conduct Virtual Event On Nov. 9 To Present Topline Data From Its Phase 2 PIK-2-1 Study Of PIKTOR To Treat Endometrial Cancer Faeth Therapeutics (NASDAQ:FTH), a clinical- stage biotechnology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a…
benzinga.com Guggenheim Maintains Buy on Faeth Therapeutics, Lowers Price Target to $69 Guggenheim analyst Michael Schmidt maintains Faeth Therapeutics (NASDAQ:FTH) with a Buy and lowers the price target from $70 to $69.
benzinga.com Faeth Therapeutics Q3 EPS $(0.79) Misses $(0.71) Estimate Faeth Therapeutics (NASDAQ:FTH) reported quarterly losses of $(0.79) per share which missed the analyst consensus estimate of $(0.71) by 11.27 percent. This is a 78.18 percent increase over losses of…
businesswire.com Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today…- benzinga.com BTIG Reiterates Buy on Faeth Therapeutics, Maintains $55 Price Target BTIG analyst Jeet Mukherjee reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $55 price target.
benzinga.com William Blair Initiates Coverage On Faeth Therapeutics with Outperform Rating William Blair analyst Alethia Young initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating.
benzinga.com Guggenheim Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $70 Guggenheim analyst Brad Canino initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $70.- benzinga.com LUCID CAPITAL MARKETS Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $59 LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $59.
benzinga.com This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Top Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. AVGO receives Outperform rating with $455 PT.- benzinga.com Needham Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $56 Needham analyst Gil Blum initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $56.
- benzinga.com Faeth Therapeutics Says FDA Grants Fast Track Designation To Combination Of Sapanisertib And Serabelisib With Paclitaxel For Treatment Of Patients With Endometrial Cancer — Fast Track designation applies to sapanisertib and serabelisib (PIKTOR) in combination with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Faeth Therapeutics, Maintains $60 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $60 price target.
- benzinga.com Faeth Therapeutics To Present Translational Data And Pharmacokinetic/Pharmacodynamic Analysis For PIKTOR, Oral Combination Of Serabelisib And Sapanisertib, At 2026 Summit For STOP Cancer — The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8— These data collectively informed PIKTOR dose selection in…
- benzinga.com Faeth Therapeutics Q2 EPS $(2.84) Beats $(3.29) Estimate Faeth Therapeutics (NASDAQ:FTH) reported quarterly losses of $(2.84) per share which beat the analyst consensus estimate of $(3.29) by 13.68 percent. This is a 27.37 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 million. Supernus…
benzinga.com This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Wall Street analysts changed outlook on top names. Check ratings page for upgrades, downgrades, initiations. See other analysts' views on HTFL, SKYH, FTH.
benzinga.com This Plexus Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday Top Wall Street analysts upgraded IP, AXTI, REPL, and PLXS stocks with higher price targets. See what other analysts think about these stocks.
benzinga.com Raymond James Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $56 Raymond James analyst Sean McCutcheon initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $56.
benzinga.com This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings page. Analysts have positive views on FTH stock.- benzinga.com Oppenheimer Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $60 Oppenheimer analyst Jay Olson initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $60.
- benzinga.com Citizens Initiates Coverage On Faeth Therapeutics with Market Outperform Rating, Announces Price Target of $51 Citizens analyst Silvan Turkcan initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Market Outperform rating and announces Price Target of $51.
- benzinga.com BTIG Reiterates Buy on Faeth Therapeutics, Maintains $55 Price Target BTIG analyst Jeet Mukherjee reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $55 price target.
benzinga.com This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Top analysts changed outlook on top names. For all changes, see analyst ratings page. See how analysts view HOOD, FXNC, NU, FTH, FRST.- benzinga.com Baird Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $57 Baird analyst Jack Allen initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $57.
benzinga.com This Principal Financial Group Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday Top Wall Street analysts changed outlook on top names. View all changes on analyst ratings page. See what analysts think of these stocks.
benzinga.com This IBM Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday Top Wall Street analysts changed outlook on top names. Piper Sandler upgraded SNPS, JP Morgan upgraded IBM,. See analyst ratings.
benzinga.com Backblaze, Infleqtion, Zeta Global And Other Big Stocks Moving Higher On Tuesday Dow Jones index fell 200+ points on Monday. Backblaze Inc rose 30.4% after $335M data storage deal with CoreWeave Inc. Other stocks also gained.
benzinga.com This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page for full coverage.
benzinga.com This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top analysts changed ratings on top stocks, including Conexeu, CRDO, AGMB, SPCX, and FTH. See what analysts say about buying CRDO stock.- benzinga.com HC Wainwright & Co. Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $60 HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $60.